Foamix Pharmaceuticals (NASDAQ:FOMX) and Tilray (NASDAQ:TLRY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Earnings and Valuation

This table compares Foamix Pharmaceuticals and Tilray’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Foamix Pharmaceuticals $3.67 million 66.64 -$65.71 million ($1.76) -3.40
Tilray N/A N/A N/A N/A N/A

Tilray has lower revenue, but higher earnings than Foamix Pharmaceuticals.

Profitability

This table compares Foamix Pharmaceuticals and Tilray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Foamix Pharmaceuticals -2,085.71% -131.84% -109.88%
Tilray N/A N/A N/A

Analyst Recommendations

This is a breakdown of current recommendations for Foamix Pharmaceuticals and Tilray, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foamix Pharmaceuticals 0 0 2 0 3.00
Tilray 0 2 1 0 2.33

Foamix Pharmaceuticals presently has a consensus price target of $9.50, suggesting a potential upside of 58.60%. Tilray has a consensus price target of $34.50, suggesting a potential downside of 65.33%. Given Foamix Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Foamix Pharmaceuticals is more favorable than Tilray.

Institutional & Insider Ownership

58.4% of Foamix Pharmaceuticals shares are held by institutional investors. 3.3% of Foamix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Foamix Pharmaceuticals beats Tilray on 6 of the 9 factors compared between the two stocks.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus. The company is also developing FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.

About Tilray

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.